FGEN noticia 19:45
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK, NY / ACCESSWIRE / November 8, 2019 / Pomerantz LLP is investigating
claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")
(NASDAQ:FGEN). Such investors are advised to contact Robert S. Willoughby at
[email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether FibroGen and certain of its officers and/or
directors have engaged in securities fraud or other unlawful business
practices.
[Click here for information about joining the class action]
(https://form.jotform.com/pomerantzllp2/FGEN)
On November 4, 2019, Plainview LLC ("Plainview") published a report
questioning the safety of Fibrogen's lead product candidate, Roxadustat, and
describing the Company as the next "biotech blow-up." The Plainview report
asserted that the FibroGen was "mysteriously unforthcoming" and misleading
investors with regards to the safety and efficacy of Roxadustat.
On this news, Fibrogen's stock price fell $3.01 per share, or 7.52%, to close
at $37.01 per share on November 4, 2019.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 80 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP
View source version on accesswire.com:
https://www.accesswire.com/565880/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-FibroGen-Inc--FGEN
Copyright 2019 ACCESSWIRE. All Rights Reserved.
Rango : negativo